A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors IMPAX Laboratories
  • Most Recent Events

    • 16 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2017 New trial record
    • 11 Jun 2017 Enrollment is planned to begin in late 2017 with results expected in 2019. The study will enroll approximately 426 subjects to randomize and treat 288.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top